[1]
|
Ferlay, J., Shin, H.R., Bray, F., et al. (2010) Estimates of Worldwide Burden of Cancer in 2008, GLOBOCAN 2008. International Journal of Cancer, 127, 2893-2917. https://doi.org/10.1002/ijc.25516
|
[2]
|
Wang, J., Liu, F., Huang D.X., et al. (2012) Post-Operative Treatment with Cisplatin and Vinorelbine in Chinese Patients with Non-Small Cell Lung Cancer: A Clinical Prospective Analysis of 451 Patients. Asian Pacific Journal of Cancer Prevention, 13, 4505-4510. https://doi.org/10.7314/APJCP.2012.13.9.4505
|
[3]
|
Ou, W., Sun, H.B., Ye, X., et al. (2010) Adjuvant Carboplatin-Based Chemotherapy in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 5, 1033-1041.
https://doi.org/10.1097/JTO.0b013e3181d95db4
|
[4]
|
Butts, C.A., Ding, K., Seymour, L., et al. (2010) Randomized Phase III Trial of Vinorelbine plus Cisplatin Compared with Observation in Completely Resected Stage IB and II Non-Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10. Journal of Clinical Oncology, 28, 29-34. https://doi.org/10.1200/JCO.2009.24.0333
|
[5]
|
Arriagada, R., Dunant, A., Pignon, J.P., et al. (2010) Long-Term Results of the International Adjuvant Lung Cancer Trial Evaluating Adjuvant Cisplatin-Based Chemotherapy in Resected Lung Cancer. Journal of Clinical Oncology, 28, 35-42. https://doi.org/10.1200/JCO.2009.23.2272
|
[6]
|
Strauss, G.M., Herndon 2nd, J.E., Maddaus, M.A., et al. (2008) Adjuvant Paclitaxel plus Carboplatin Compared with Observation in Stage IB Non-Small-Cell Lung Cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. Journal of Clinical Oncology, 26, 5043-5051. https://doi.org/10.1200/JCO.2008.16.4855
|
[7]
|
Park, S.Y., Lee, J.G., Kim, J., et al. (2013) Efficacy of Platinum-Based Adjuvant Chemotherapy in T2aNO Stage IB Non-Small Cell Lung Cancer. Journal of Cardiothoracic Surgery, 8, 151. https://doi.org/10.1186/1749-8090-8-151
|
[8]
|
Pignon, J.P., Tribodet, H., Scagliotti, G.V., et al. (2008) Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group. Journal of Clinical Oncology, 26, 3552-3559.
https://doi.org/10.1200/JCO.2007.13.9030
|
[9]
|
Arriagada, R., Auperin, A., Burdett, S., et al. (2010) Adjuvant Chemotherapy, with or without Postoperative Radiotherapy, in Operable Non-Small-Cell Lung Cancer: Two Meta-Analyses of Individual Patient Data. Lancet, 375, 1267-1277. https://doi.org/10.1016/S0140-6736(10)60059-1
|
[10]
|
Douillard, J.Y., Rosell, R., De Lena, M., et al. (2008) Impact of Postoperative Radiation Therapy on Survival in Patients with Complete Resection and Stage I, II, or IIIA Non-Small-Cell Lung Cancer Treated with Adjuvant Chemotherapy: The Adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial. International Journal of Radiation Oncology * Biology * Physics, 72, 695-701. https://doi.org/10.1016/j.ijrobp.2008.01.044
|
[11]
|
Douillard, J.Y., Rosell, R., De Lena, M., et al. (2006) Adjuvant Vinorelbine plus Cisplatin versus Observation in Patients with Completely Resected Stage IB-IIIA Non Small-Cell Lung Cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A Randomised Controlled Trial. The Lancet Oncology, 7, 719-727.
https://doi.org/10.1016/S1470-2045(06)70804-X
|
[12]
|
Kreuter, M., Vansteenkiste, J., Fishcer, J.R., et al. (2013) Randomized Phase 2 Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine: The TREAT Study. Annals of Oncology, 24, 986-992. https://doi.org/10.1093/annonc/mds578
|
[13]
|
Albain, K.S., Crowley, J.J., Turrisi, A.T. III, et al. (2002) Concurrent Cisplatin, Etoposide,and Chest Radiotherapy in Pathologic Stage IIIB Non-Small-Cell Lung Cancer: A Southwest Oncology Group Phase II Study, SWOG 9019. Journal of Clinical Oncology, 20, 3454-3460. https://doi.org/10.1200/JCO.2002.03.055
|
[14]
|
Curran, W.J. Jr., Paulus, R., Langer, C.J., et al. (2011) Sequential vs. Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410. Journal of the National Cancer Institute, 103, 1452-1460. https://doi.org/10.1093/jnci/djr325
|
[15]
|
Socinski, M.A., Bondarenko, I., Karaseva, N.A., et al. (2012) Weekly Nab-Paclitaxel in Combination with Carboplatin versus Solvent-Based Paclitaxel plus Carboplatin as First-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer: Final Results of a Phase III Trial. Journal of Clinical Oncology, 30, 2055-2062.
|
[16]
|
Shaw, A.T., Yeap, B.Y., Solomon, B.J., et al. (2011) Effect of Crizotinib on Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Harbouring ALK Gene Rearrangement: A Retrospective Analysis. The Lancet Oncology, 12, 1004-1012. https://doi.org/10.1016/S1470-2045(11)70232-7
|
[17]
|
Sequist, L.V., Yang, J.C.-H., Yamamoto, N., et al. (2013) Phase III Study of Afatinib or Cisplatin plus Pemetrexed in Patients with Metastatic Lung Adenocarcinoma with EGFR Mutations. Journal of Clinical Oncology.
|
[18]
|
孙建立, 李春杰, 李和根, 刘苓霜, 田建辉. 刘嘉湘扶正法治癌学术思想介绍[J]. 中医杂志, 2006(11): 814-816.
|
[19]
|
徐坚, 胡作为. 肺癌的中医致病机理探讨[J]. 黑龙江中医药, 2013, 3: 11-12.
|
[20]
|
Rotolo, F., Dunant, A., Le Chevalier, T., et al. (2014) Adjuvant Cisplatin-Based Chemotherapy in Nonsmall-Cell Lung Cancer: New Insights into the Effect on Failure Type via a Multistate Approach. Annals of Oncology, 25, 2162-2166.
|
[21]
|
李素霞, 杨凡, 刘丽娜. 软坚散联合盐酸吉西他滨和顺铂化疗方案治疗肺癌术后化疗患者120例[J]. 中医研究, 2014, 7: 21-23.
|
[22]
|
Xu, L., Li, H., Xu, Z., et al. (2012) Multi-Center Randomized Double-Blind Controlled Clinical Study of Chemotherapy Combined with or without Traditional Chinese Medicine on Quality of Life of Postoperative Non-Small Cell Lung Cancer Patients. BMC Complementary and Alternative Medicine, 12, 112.
|
[23]
|
张斌杰, 张永奎, 乐涵波, 等. 非小细胞肺癌术后化疗配合蟾蝓保元汤治疗的作用[J]. 中国中西医结合外科杂志, 2011, 5: 458-460.
|
[24]
|
郑爱红, 吴国清, 薛骞, 等. 扶正抗癌汤对肺癌术后的临床疗效观察[J]. 中华中医药学刊, 2013, 3: 698-700.
|
[25]
|
唐洪成, 陈光伟. 百合固金汤联合NP方案治疗中晚期非小细胞肺癌30例疗效观察[J]. 长春中医药大学学报, 2011, 4: 615-616.
|
[26]
|
寿伟臻, 俞杞泉, 朱正洪, 等. 金宁方加味对Ⅲ期非小细胞肺癌患者术后抗复发转移临床评价[J]. 上海中医药杂志, 2014, 8: 30-33.
|
[27]
|
章晓毅, 叶建明, 鲍献荣. 中药五味汤联合吉西他滨顺铂在肺癌术后辅助化疗中的疗效观察[J]. 中华中医药学刊, 2013, 6: 1455-1457.
|
[28]
|
齐拥军. 参芪扶正注射液对肺癌术后化疗患者生存质量[J]. 中国医院用药评价与分析, 2012, 12(11): 1020-1021.
|
[29]
|
吴贤, 叶圣雅, 谢炳銮. 得力生注射液在非小细胞肺癌术后化疗中的作用[J]. 中国中西医结合外科杂志, 2010, 4: 412-414.
|
[30]
|
朱丽华, 李和根, 史美育, 等. 非小细胞肺癌根治术后无瘤生存期影响因素分析及中药干预效果评价[J]. 上海中医药杂志, 2013, 47(2): 11-15.
|
[31]
|
张清琴, 寇小格, 田小军, 等. 人参皂苷Rg3对肺癌术后长期生存的影响观察[J]. 中国医疗前沿, 2010, 5(4): 42-43.
|
[32]
|
王中奇, 徐振晔, 邓海滨, 等. 中医药结合化疗防治非小细胞肺癌术后复发转移的临床研究[J]. 上海中医药杂志, 2011, 5: 36-39.
|
[33]
|
李远静, 骆学新, 孟小鹏, 等. 非小细胞肺癌患者术后化疗结合中医辅助治疗的中期疗效观察[J]. 中华中医药学刊, 2013, 31(11): 2564-2566.
|
[34]
|
施松泉. 艾迪注射液联合NP方案治疗非小细胞肺癌根治术后26例[J]. 浙江中医杂志, 2011, 46(11): 806.
|
[35]
|
温士旺, 张月峰, 李勇, 等. 五味汤联合吉西他滨顺铂对非小细胞肺癌术后辅助化疗的影响[J]. 中国实验方剂学杂志, 2014, 16: 184-186.
|
[36]
|
龙谦, 刘迪, 唐维娟. 肺癌术后化疗联合服用复方斑蝥胶囊的临床观察[J]. 内蒙古中医药, 2013, 19: 10-11.
|
[37]
|
章慧, 王云启, 梁慧. 八珍汤加减治疗非小细胞肺癌术后化疗致骨髓抑制20例总结[J]. 湖南中医杂志, 2011, 6: 23-25.
|
[38]
|
尚立群, 王伟, 李学昌, 等. 康艾注射液在ⅢA期非小细胞肺癌术后辅助化疗中的应用[J]. 中华临床医师杂志(电子版), 2011, 15: 4509-4511.
|
[39]
|
刘亚州, 董家寿, 易军, 等. 术后化疗联合中医辅助疗法治疗非小细胞肺癌临床研究[J]. 河南中医, 2014, 6: 1111-1113.
|
[40]
|
莫绍雄, 杨小平, 吴军. 益气养阴化痰法在非小细胞肺癌术后化疗中的应用[J]. 浙江中西医结合杂志, 2011, 10: 705-706.
|
[41]
|
刘陶东, 张羽捷. 非小细胞肺癌术后应用艾迪注射液辅助化疗临床观察[J]. 中国药物与临床, 2013, 1: 116-117.
|
[42]
|
亓宪银, 刘民杰. 复方苦参注射液对肺癌术后化疗患者免疫功能的影响[J]. 现代肿瘤医学, 2014, 1: 84-86.
|
[43]
|
莫绍雄. 鸦胆子油乳联合化疗对非小细胞肺癌术后患者免疫功能的影响[J]. 现代中西医结合杂志, 2010, 9: 1098-1099.
|
[44]
|
俞杞泉, 张嗣博, 柳涛. 术后化痰方干预非小细胞肺癌术后围手术期的多中心随机双盲对照研究[J]. 上海中医药大学学报, 2014, 2: 23-25 + 30.
|
[45]
|
Westeel, V., Quoix, E., Puyraveau, M., et al. (2013) A Randomised Trial Comparing Preoperative to Perioperative Chemotherapy in Early-Stage Non-Small-Cell Lung Cancer (IFCT 0002 Trial). European Journal of Cancer, 49, 2654-2664.
|